Total RNA Purification Plus Kit
For the purification of total RNA - including microRNA - with rapid gDNA removal
For research use only and NOT intended for in vitro diagnostics.
Total RNA Purification Plus Kit
For the purification of total RNA - including microRNA - with rapid gDNA removal
Register today to receive an exclusive 15% off* on your first order.
Features and Benefits
- Extract high quality & quantity total RNA including miRNA
- No phenol step required; isolate all RNA in one fraction
- Genomic DNA Removal Column for efficient elimination of gDNA
- Bind & elute all RNA irrespective of size or GC content, without bias
- Efficiently extract small RNA irrespective of GC content
- Very sensitive & linear down to a few cells without the need for carrier RNA
- Convenient & fast spin column format
- Isolate from a wide variety of specimens
- Purification is based on spin column chromatography that uses Norgen’s proprietary resin separation matrix
This kit purifies total RNA including miRNA from biological samples and employs an extra column for the efficient removal of contaminating gDNA, thereby replacing the enzymantic DNase step.
Efficiently extract total RNA from a range of samples including cells, bacteria, yeast, virus and bodily fluids including plasma/serum, blood, saliva, CSF and more. Extract high quality and purity RNA with excellent RIN values and A260/A280 suitable for downstream applications including qRT-PCR, RT-PCR, microarrays, NGS and more.
The kit purifies all sizes of RNA from large mRNA, lncRNA down to microRNA (miRNA) in the same fraction without the requirement of phenol. Isolate all RNA sequences at an equal rate irrespective of size. Moreover, when the RNA sequences are small (e.g. miRNA), the column binds small RNAs regardless of their GC content.
Details
Supporting Data
Kit Specifications
|
|||
Maximum Binding Capacity Per Column
|
Up to 50 μg RNA
|
||
Maximum Loading Volume Per Spin Column
|
650 μL
|
||
Size of RNA Purified
|
All sizes, including < 200 nt
|
||
Time to Complete 10 Purifications |
25 minutes
|
||
Maximum Amount of Starting Material
|
|||
Liver Tissue
|
20 mg
|
||
Heart Tissue
|
5 mg
|
||
Kidney Tissue
|
20 mg
|
||
Brain Tissue
|
25 mg
|
||
Lung Tissue |
20 mg
|
||
Spleen Tissue
|
20 mg
|
||
Whole Blood
|
100 µL
|
||
Hela Cells
|
3 x 106
|
||
CHO |
3 x 106
|
||
Yeast |
1 x 108 cells
|
||
E.coli |
1 x 109 CFU/mL
|
||
Bacteria | 1 x 109 cells | ||
Plasma/Serum | 200 µL | ||
Fungi |
50 mg
|
||
Plant Tissue |
50 mg
|
||
Viruses |
≤100 µL of viral suspension
|
||
Average Yield
|
|||
|
All solutions should be kept tightly sealed and stored at room temperature. This kit is stable for 1 year after the date of shipment.
Component | Cat. 48300 (50 preps) | Cat. 48400 (100 preps) |
---|---|---|
Buffer RL | 40 mL | 2 x 40 mL |
Wash Solution A | 38 mL | 2 x 38 mL |
Elution Solution A | 6 mL | 2 x 6 mL |
RNA Purification Columns | 50 | 100 |
Genomic DNA Removal Columns | 50 | 100 |
Collection Tubes | 100 | 200 |
Elution Tubes (1.7 mL) | 50 | 100 |
Product Insert | 1 | 1 |
Documentation
FAQs
Plus
Poor RNA recovery could be due to one or more of the following:
- Incomplete lysis of cells or tissue. Ensure that the appropriate amount of Buffer RL was used for the amount of cells or tissue.
- Column has become clogged. Either the Genomic DNA Removal Column or the RNA Purification Column may become clogged if the recommended amount of starting materials is exceeded. The amount of starting material may need to be decreased if the column shows clogging below the recommended levels. See FAQ related to “Clogged Column” below.
- An alternative elution solution was used. It is recommended that the Elution Solution A supplied with this kit be used for maximum RNA recovery.
- Ethanol was not added to the lysate. Ensure that the appropriate amount of ethanol is added to the lysate before binding to the column.
- Ethanol was not added to the Wash Solution A. Ensure that 90 mL of 96 - 100% ethanol is added to the supplied Wash Solution A prior to use.
- Low RNA content in cells or tissues used. Different tissues and cells have different RNA contents, and thus the expected yield of RNA will vary greatly from these different sources. Please check literature to determine the expected RNA content of your starting material.
- Cell Culture: Cell monolayer was not washed with PBS. Ensure that the cell monolayer is washed with the appropriate amount of PBS in order to remove residual media from cells.
- Yeast: Lyticase was not added to the Resuspension Buffer. Ensure that the appropriate amount of lyticase is added when making the Resuspension Buffer.
- Bacteria and Yeast: All traces of media not removed. Ensure that all media is removed prior to the addition of Buffer RL through aspiration.
Column clogging can result from one or a combination of the following factors:
- Insufficient solubilization of cells or tissues. Ensure that the appropriate amount of lysis buffer was used for the amount of cells or tissue.
- Maximum number of cells or amount of tissue exceeds kit specifications. Refer to specifications to determine if the amount of starting material falls within kit specifications.
- High amounts of genomic DNA present in sample. The lysate may be passed through a 25 gauge needle attached to a syringe 5-10 times in order to shear the genomic DNA prior to loading onto the column.
- Centrifuge temperature is too low. Ensure that the centrifuge remains at room temperature throughout the procedure. Temperatures below 15°C may cause precipitates to form that can cause the columns to clog.
RNA can be degraded due to the following factors:
- RNase contamination. RNases may be introduced during the use of the kit. Ensure proper procedures are followed when working with RNA. Please refer to “Working with RNA” at the beginning of this user guide.
- Procedure not performed quickly enough. In order to maintain the integrity of the RNA, it is important that the procedure be performed quickly. This is especially important for the Cell Lysate Preparation Step in the Tissue Protocol, since the RNA in animal tissues is not protected after harvesting until it is disrupted and homogenized.
- Improper storage of the purified RNA. For short-term storage, RNA samples may be stored at –20°C for a few days. It is recommended that samples be stored at –70°C for longer-term storage.
- Frozen tissues were allowed to thaw prior to RNA isolation. Do not allow frozen tissues to thaw prior to grinding with a mortar and pestle in order to ensure that the integrity of the RNA is not compromised.
- Starting material may have a high RNase content. For starting materials with high RNase content, it is recommended that β-mercaptoethanol be added to the Lysis Solution.
- Lysozyme or lyticase used may not be RNase-free. Ensure that the lysozyme and lyticase being used with this kit are RNase-free, in order to prevent possible problems with RNA degradation.
If the RNA does not perform well in downstream applications, it may be due to one or more of the following:
- RNA was not washed 3 times with the provided Wash Solution A. Traces of salt from the binding step may remain in the sample if the plate is not washed 3 times with Wash Solution A. Salt may interfere with downstream applications, and thus must be washed from the column.
- Ethanol carryover. Ensure that the dry spin under the Column Wash Procedure is performed, in order to remove traces of ethanol prior to elution. Ethanol is known to interfere with many downstream applications.
The contamination with genomic DNA may be due to large amount of starting material used. Perform RNase-free DNase I digestion on the RNA sample after elution to remove genomic DNA contamination. It is recommended that Norgen’s RNase-Free DNase I Kit (Product # 25710) be used for this step.
The Total RNA Purification "Plus" kit comes with gDNA removal columns for efficient removal of genomic DNA.
Citations
Title | MicroRNA-409-3p/BTG2 signaling axis improves impaired angiogenesis and wound healing in obese mice |
Citation | The FASEB Journal 2024. |
Authors | Furkan Bestepe, George F. Ghanem, Colette M. Fritsche, James Weston, Sumedha Sahay, Amanda K. Mauro, Parul Sahu, Sude M. Tas, Brooke Ruemmele, Sarah Persing, Miranda E. Good, Abhishek Chatterjee, Gordon S. Huggins, Payam Salehi, Basak Icli |
Title | Familial childhood onset, slowly progressive myopathy plus cardiomyopathy expands the phenotype related to variants in the TTN gene |
Citation | Neuromuscular Disorders 2024. |
Authors | Alessia Perna a, Luca Bosco b c, Fabiana Fattori d, Eleonora Torchia a, Anna Modoni e, Manuela Papacci a, Antonio Petrucci f, Giorgio Tasca e #, Enzo Ricci a e, Enrico Silvio Bertini b, Gabriella Silvestri |
Title | Gene and lncRNA Profiling of ?3/?6 Polyunsaturated Fatty Acid-Exposed Human Visceral Adipocytes Uncovers Different Responses in Healthy Lean, Obese and Colorectal Cancer-Affected Individuals |
Citation | International Journal of Molecular Sciences 2024. |
Authors | Sabrina Tait 1 , Enrica Calura 2 , Antonella Baldassarre 3 , Andrea Masotti 3 , Barbara Varano 1 , Sandra Gessani 4 , Lucia Conti 1,* and Manuela Del Cornò |
Title | Genetically Engineered Macrophages Derived from iPSCs for Self-Regulating Delivery of Anti-Inflammatory Biologic Drugs |
Citation | Journal of tissue engineering and regenerative medicine 2024. |
Authors | Molly Klimak 1,2,3,4and Farshid Guilak |
Title | Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors |
Citation | Antiviral Research 2024. |
Authors | Marta Trevisan a, Anna Pianezzola a, Marco Onorati b, Lorenzo Apolloni a, Mauro Pistello c, Ravit Arav-Boger d, Giorgio Palù a, Beatrice Mercorelli a 1, Arianna Loregian |
Title | Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs |
Citation | Cellular Signalling 2024. |
Authors | Esther Sathya Bama Benjamin a d, Elizabeth Vinod b c, Raveen Stephen Stallon Illangeswaran a, Bharathi M. Rajamani a, Rakhi Thalayattu Vidhyadharan a, Abhirup Bagchi c, Arnab Maity a, Ajith Mohan a, Ganesh Parasuraman b, Soosai Manickam Amirtham b, Aby Abraham a, Shaji R Velayudhan a c, Poonkuzhali Balasubramanian |
Title | Transcriptomic analysis reveals the anti-cancer effect of gestational mesenchymal stem cell secretome |
Citation | Stem Cells Translational Medicine 2024. |
Authors | Salvatore Vaiasicca, Gianmarco Melone, David W James, Marcos Quintela, Jing Xiao, Seydou Yao, Richard H Finnell, Robert S Conlan, Lewis W Francis, Bruna Corradetti |
Title | VDAC1-interacting molecules promote cell death in cancer organoids through mitochondrial-dependent metabolic interference |
Citation | ISCIENCE 2024. |
Authors | Stefano Conti Nibali, Silvia De Siervi, Enrico Luchinat, Andrea Magrì, Angela Messina, Lorenza Brocca, Stefania Mantovani, Barbara Oliviero, Mario U. Mondelli, Vito De Pinto, Cristian Turato, Cristina Arrigoni, Marco Lolicato |
Title | Valine Catabolism Drives Bioenergetic and Lipogenic Fuel Plasticity in Prostate Cancer |
Citation | Preprint BIORXIV 2024. |
Authors | Charles L. Bidgood1† , Lisa K. Philp1 , Anja Rockstroh1 , Melanie Lehman1,2, Colleen C. Nelson1 3 , Martin C. Sadowski3 , and Jennifer H. Gunter1† |
Title | Isolated Valve Amyloid Deposition in Aortic Stenosis: Potential Clinical and Pathophysiological Relevance |
Citation | International Journal of Molecular Sciences 2024. |
Authors | Maddalena Conte 1,2,†ORCID,Paolo Poggio 3,†,Maria Monti 4,5ORCID,Laura Petraglia 1,Serena Cabaro 1,Dario Bruzzese 6ORCID,Giuseppe Comentale 7ORCID,Aurelio Caruso 2,Mariagabriella Grimaldi 2,Emilia Zampella 7ORCID,Annarita Gencarelli 7,Maria Rosaria Cervasio 7,Flora Cozzolino 4,5ORCID,Vittoria Monaco 4,5ORCID,Veronika Myasoedova 3ORCID,Vincenza Valerio 3,Adele Ferro 8,Luigi Insabato 7ORCID,Michele Bellino 9,Gennaro Galasso 9ORCID,add Show full author list |